--- a
+++ b/clusters/3009knumclusters/clust_138.txt
@@ -0,0 +1,183 @@
+Have severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
+Has a known hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or T-DM1 or any of their excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+COHORT 1: Hypersensitivity to pembrolizumab or any of its excipients
+COHORT 2: Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients.
+Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients
+Known hypersensitivity to any component of PVX-410, Hiltonol, Montanide, pembrolizumab, or excipients
+Has severe hypersensitivity to pembrolizumab and/or any of its excipients and/or to ipilimumab and/or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+History of allergic reactions or hypersensitivity to pembrolizumab or any of its excipients
+Has severe hypersensitivity (?Grade 3) to pembrolizumab and/or any of its excipients
+Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its recipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has participated in any other pembrolizumab trial and has been treated with pembrolizumab.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has a known hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients.
+Patient has a known hypersensitivity to any of the excipients of bavituximab or pembrolizumab or monoclonal antibody
+Hypersensitivity to pembrolizumab or any of its excipients
+Has serious hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
+Hypersensitivity to pembrolizumab or sunitinib or any of their excipients
+Has hypersensitivity to pembrolizumab, epacadostat or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or lenvatinib or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Known hypersensitivity to pembrolizumab or any of its excipients
+Has severe hypersensitivity (>= grade 3) to pembrolizumab or any of its excipients.
+Has severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients
+Had a severe hypersensitivity reaction to treatment with pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or paricalcitol or any of its excipients.
+Has hypersensitivity to pembrolizumab, gadolinium, or ferumoxytol or any of their excipients
+Has a known history of hypersensitivity to pembrolizumab or any of its excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to PBZ or any of its excipients
+Hypersensitivity to pembrolizumab or any of its recipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has severe hypersensitivity to pembrolizumab or any of its excipients
+Has hypersensitivity to either study drug or any of the excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has known hypersensitivity to pembrolizumab and/or epacadostat or any of their excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Known hypersensitivity to BGB324, pembrolizumab, or any of their excipients.
+Hypersensitivity to ibrutinib or pembrolizumab or any of their excipients
+Severe hypersensitivity to pembrolizumab or any of its excipients
+Known hypersensitivity to pembrolizumab or any of its excipients
+History of hypersensitivity to pembrolizumab, docetaxel, gemcitabine, pemetrexed or any of their excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or lanreotide or any of their excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Known or presumed hypersensitivity to decitabine or pembrolizumab (or any of their excipients)
+Hypersensitivity to pembrolizumab or ibrutinib or any of their excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to bevacizumab, cyclophosphamide, pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab, azacitidine, mannitol, or any of their excipients
+Has a known hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab, vorinostat or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients.
+Hypersensitivity to pembrolizumab, any of its excipients, paclitaxel, or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has hypersensitivity to pembrolizumab, docetaxel or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has severe hypersensitivity (?Grade 3) to pembrolizumab, MK-4280, or lenvatinib and/or any of its excipients
+Severe hypersensitivity (? Grade 3) to pembrolizumab and/or any of its excipients.
+Known hypersensitivity or intolerance to any of the active substance or excipients in the formulations for pembrolizumab and blinatumomab
+REGISTRATION TO TREATMENT (STEP 1): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients
+REGISTRATION TO TREATMENT (STEP 2): Patient must not have a history of hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or epacadostat or any of their excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab, epacadostat or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to MK-3475 (pembrolizumab) or any of its excipients;
+Hypersensitivity to pembrolizumab, binimetinib, or any excipients of either drug
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients, or a known history of hypersensitivity to IL-2 or any component of the formulation
+Hypersensitivity to pembrolizumab or any of its excipients
+Has severe hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
+Prior known allergic reaction to pembrolizumab or its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has a known severe hypersensitivity (> Grade 3) to pembrolizumab, its active substance and/or any of its excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Has a known severe hypersensitivity to pembrolizumab, its active substance and/or any of its excipients
+Known hypersensitivity to pembrolizumab or any of its insipients
+Severe hypersensitivity to any pembrolizumab excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Known hypersensitivity to pembrolizumab or any of its excipients and/or liposomal doxorubicin
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has known hypersensitivity to pembrolizumab or any of its excipients
+Known hypersensitivity to pembrolizumab or any of its excipients.
+Known allergy to pembrolizumab or any of its excipients.
+Has severe hypersensitivity (? Grade 3) to any study treatment (pembrolizumab, cisplatin, or 5-FU) and/or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has severe hypersensitivity (Grade ?3) to pembrolizumab and/or any of its excipients
+Has hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab, imatinib, or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Prior pembrolizumab
+Hypersensitivity to pembrolizumab or any of it's excipients.
+Hypersensitivity to the active substance or any other excipients of the eribulin mesylate drug product, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients.
+Hypersensitivity to pembrolizumab or any of its excipients
+Has hypersensitivity to pembrolizumab or any of its excipients
+Patients with known hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has a known severe hypersensitivity (? Grade 3) to pembrolizumab, its active substance and/or any of its excipients, or to any of the study chemotherapy agents and/or to any of their excipients.
+Patients must not have a hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients
+Has hypersensitivity to the active substance or to any of the excipients in BV or pembrolizumab.
+Hypersensitivity to pembrolizumab or any of its excipients
+Hypersensitivity to pembrolizumab or any of its excipients